妊娠期抗病毒治疗阻断HBV母婴传播的新进展OA北大核心CSTPCD

Mother-to-child transmission of hepatitis B virus(HBV)is one of the primary causes of the high disease burden of chronic hepatitis B in China,and blocking this route of transmission has an important strategic significance for eliminating hepatitis B.While immediate combined immunoprophylaxis for neonates upon birth is the fundamental strategy to block the mother-to-child transmission of HBV,there is still a mother-to-child transmission rate of 9%in mothers with high viral loads.In recent years,breakthroughs have been made in the research on antiviral therapy during pregnancy for blocking mother-to-child transmission,which marks a pivotal milestone in eliminating the mother-to-child transmission of hepatitis B.Comprehensive prophylaxis of antiviral therapy during pregnancy and immunoprophylaxis for infants after birth has become the key strategy for eliminating the mother-to-child transmission of hepatitis B.This article summarizes the development and latest advances in antiviral therapy during pregnancy for blocking mother-to-child transmission,as well as related intervention strategies and indications,in order to provide a reference for clinicians and public health physicians.